■ INTRODUCTION
Sirtuins (SIRTs) compose class III of lysine deacetylases (KDACs). There are seven conserved human isoforms (SIRT1−SIRT7) with different subcellular locations. 1 The enzymes catalyze the reversible deacetylation of lysine residues both on histones (H1, H3, H4) and nonhistone proteins, e.g., p53, p65, PGC-1α, PPARγ, FOXO, NFκB, and α-tubulin. 2 The deacetylation reaction requires nicotinamide adenine dinucleotide (NAD + ) as cosubstrate, and results in the formation of the deacetylated protein substrate, O-acetyl-ADP-ribose, and nicotinamide, which is the endogenous inhibitor of the sirtuins. 3−5 In addition to the deacetylation, also mono-ADPribosyl transferase activity and removal of long-chain fatty acyl groups from lysine residues have been reported for SIRT6. 6−8 Mono-ADP-ribosyl transferase activity is the only effect observed for SIRT4. 9 Recently, Du et al. discovered lysine demalonylation and desuccinylation activities of SIRT5, 10 which later was followed by reports by Zhao and co-workers regarding deglutarylation from lysine residues as a function of SIRT5. 11 Because of the broad spectrum of substrates, SIRTs have been implicated as regulators in a range of physiological processes, including metabolism, cell survival and apoptosis, gene expression, and DNA repair. 12 Therefore, the enzymes have been proposed to be involved in pathologies such as inflammation and aging-associated diseases, e.g., cancer, diabetes, and neurodegeneration (e.g., Alzheimer's, Huntington's, and Parkinson's disease). 13, 14 The potent SIRT1 inhibitor selisistat (36 (Ex-527), Chart 2) reduces Huntington's disease pathology 15 and has been in phase II clinical studies. 16 SIRT2, which is the focus of the present study, is predominantly located in the cytoplasm but is enriched in the nucleus during mitosis. 17 Beside the deacetylation of histone H4, the enzyme is also involved in the deacetylation of nonhistone substrates such as α-tubulin, FOXO, p65, p300, and p53. 18 Hence, the enzyme is proposed to be involved in the regulation of the cell cycle. 19 SIRT2 is highly expressed in the brain, 18 and inhibition appears to be neuroprotective as two SIRT2 selective inhibitors have been shown to counteract progression of Huntington's 20, 21 and Parkinson's disease. 22 Regarding its role in oncogenesis, there are contradictory reports in the literature whether SIRT2 is a tumor suppressor or promoter. 23−25 Downregulation of SIRT2 reduced the cell proliferation in glioma cells, 26 HeLa cells, 27 and liver 28 and pancreatic carcinomas. 29 Inhibition of SIRT2 by selective inhibitors such as 30 (AGK-2, Chart 2) and a 10,11-dihydro-5H-dibenz[b,f ]azepine derivative have been shown to induce apoptosis in C6 glioma cells 26 and MCF-7 breast cancer cells, 30 respectively. Other small-molecule SIRT2 inhibitors have shown to reduce cancer proliferation via the increase in p53 acetylation in nonsmall-cell lung cancer cells (A549 and H1299). 31 Hence, SIRT2 has been considered to be an interesting target for cancer drug development.
Recently, we showed that trisubstituted 2-alkyl-chroman-4-ones can serve as selective SIRT2 inhibitors with IC 50 values in the low micromolar range. 32 Two of the most potent inhibitors are shown in Chart 1.
The structure−activity relationship (SAR) study revealed that electron-withdrawing groups on the aromatic ring of the bicycle, the carbonyl group, as well as an alkyl side chain in the 2-position are crucial for potent inhibitors. The SAR study also disclosed an exceptionally close relationship between the presence of all features mentioned above and the inhibitor potency as even minor modifications resulted in a severe loss of activity. Analysis of the individual enantiomers of 1 showed that the stereoisomers had only small differences in inhibitory activities, with (S)-1 being slightly more potent (Chart 1).
However, the high lipophilicity of the published chroman-4-ones limits their use in more advanced biological in vivo and in vitro tests. Herein, we report chroman-4-one analogues based on lead compounds 1 and 2 as potential SIRT2 inhibitors with increased hydrophilicity. The hydrophilicity was increased by the introduction of heterofunctional groups such as terminal hydroxyl, carboxylic acid, ester, and amide moieties in the alkyl side chain in the 2-position of 1. The phenyl ring in 2 was replaced with aromatic and aliphatic heterocycles. We also propose a binding mode of the chroman-4-ones based on a homology model of SIRT2. It showed to be consistent with the SAR data of the investigated compounds. Two potent inhibitors were chosen for further evaluation of their effect on cancer cells.
■ RESULTS AND DISCUSSION
Chemistry. The key reaction in the synthesis of the biologically evaluated compounds is the assembling of the chroman-4-one scaffold. The general synthetic strategy for the formation of chroman-4-ones 6a−i is shown in Scheme 1 and involves the base-promoted aldol condensation between a substituted 2′-hydroxyacetophenone and an aldehyde, followed by an intramolecular oxa-Michael ring closure reaction. Commercially available alcohols (3a, 3d−g) were used as precursors for the desired aldehydes, whereas alcohols 3b and 3c were synthesized via monoprotection of commercially available diols using NaH and TBDMSCl according to a procedure reported by McDougal et al. 33 The aldehydes (4a− g) were obtained via Swern or Dess−Martin oxidation and could be directly used in the next step without any further purification. For the ethylene glycol based aldehyde 4d, the ordinary workup procedure involving addition of water and EtOAc had to be changed to a nonaqueous workup due to its high water solubility.
The chroman-4-ones 5a−c and 6d−i were synthesized in moderate to good yields by heating 2′-hydroxyacetophenones and the appropriate aldehydes in a microwave reactor for 1 h in ethanol using N,N-diisopropylamine (DIPA) as base. The TBDMS-protection group of 5a−c was removed using electrophilic fluorine in a microwave-heated reaction, 34 providing the deprotected chroman-4-ones 6a−c in 16−78% yield over three steps. Removal of the silyl protecting group of 5a and 5b with the more commonly used tetrabutylammonium fluoride (TBAF) in THF surprisingly yielded the ring opened products 7a and 7b (Scheme 2). No formation of the ringopened byproduct was observed for 5c. Treatment of the hydroxyl derivatives 6a and 6b with TBAF also resulted in the formation of ring opened products. The byproduct formation is likely to be attributed to the basicity of the fluoride ion in organic solvents. In separate experiments, it was however found b Commercially available hexanal (4h) was used.
that the byproduct was not formed when triethylamine was used as base. The ester analogues of 6a and 6b were prepared according to the synthetic route outlined in Scheme 3. δ-Valerolactone and γ-butyrolactone were ring-opened under basic conditions in MeOH. Alcohol oxidation provided aldehydes 8a and 8b, which were reacted with 3′-bromo-5′-chloro-2′-hydroxyacetophenone to afford 9a and 9b (Scheme 3).
As esters are prone to hydrolyze in vivo, we also wanted to test the corresponding carboxylic acid analogues for their SIRT2 inhibitory potency, as well as amide and oxadiazole analogues, which are hydrolytically more stable and also considered to be ester bioisosteres. Chroman-4-ones 9a−b were believed to be good starting points to access the carboxylic acids as well as the different amide analogues. However, attempts to hydrolyze the ester functionality of 9b under basic conditions (LiOH or Me 3 SnOH) were unsuccessful. Neither were attempts to obtain the amide analogues by directly reacting 2-hydroxyacetophenones with δ-amido aldehydes, obtained by ring opening of δ-valerolactone with amines followed by oxidation of the obtained amido alcohols, successful.
Instead, oxidation of the primary alcohol of 6a and 6b by a Dess−Martin oxidation, followed by a Pinnick oxidation of the generated aldehydes, yielded the carboxylic acids 10a−b (Scheme 4). The acids were then successfully coupled with different primary and secondary amines using N,N′-carbonyldiimidazole (CDI) as coupling reagent to provide amides 11a−e in good to excellent yields (68−93%). Treatment of the CDI-activated acids 10a or 10b with acetamide oxime followed by heating provided the oxadiazoles 12a−b.
To further explore the influence of the phenyl ring in lead compound 2 (Chart 1), pyridine rings (6e−g) and morpholine, piperidine, or piperazine moieties were planned to be incorporated. The latter chroman-4-ones were envisioned to be synthesized in analogy to the standard route outlined in Scheme 1 starting from commercially available alcohols as precursors (Scheme 5). However, neither Swern oxidation of 3-morpholinopropan-1-ol nor the use of other oxidizing agents such as Dess−Martin periodinane, TEMPO, TPAP, or CrO 3 35 resulted in the desired aldehyde 13. Finally, 13 was obtained by conjugate addition of morpholine to acrolein (Scheme 5). Applying the standard procedure for approaching target compound 14a was unsuccessful as well as attempts via preformation of the aldol intermediate using of lithium diisopropylamide (LDA). Attempts to approach the aliphatic heterocycles containing chroman-4-ones via a substitution reaction of a terminal hydroxyl group failed due to the unsuccessful reaction of the acetophenone and aldehyde 15. None of the approaches resulted in the formation of the desired products.
Eventually, the prolongation of the spacer between the chroman-4-one scaffold and the heterocycle to propylene enabled the synthesis of related analogues of the phenethylsubstituted chroman-4-one 2. The synthetic pathway toward the derivatives is outlined in Scheme 6. Compounds 17a and 17b were finally prepared from the mesylated chroman-4-one 16 via a microwave-assisted substitution reaction using morpholine and piperidine.
In addition to the above-described monocyclic heterofunctionalities, bicyclic groups were introduced to move the hydrogen-bonding groups further away from the scaffold. Two different ring systems were chosen, i.e., quinolin-6-yl and 3,4-dihydro-2(1H)-quinolinone-6-yl. The starting material 6-bromo-3,4-dihydro-2(1H)-quinolinone was prepared in analogy to the procedure reported by Tietze et al. 36 and Zaragoza et al. 37 Reaction of the bromo-substituted bicyclic systems with acetal-protected acrolein in a Heck reaction yielded 18a−b (Scheme 7). 38 Catalytic hydrogenation and deprotection of the acetal under acidic conditions furnished the desired aldehyde 
19a (Scheme 7)
. Surprisingly, under the mild reducing conditions (H 2 -balloon, 10% Pd/C, room temp) chosen to reduce the aliphatic double bond in 18b also the quinoline moiety was reduced to yield the corresponding 1,2,3,4-tetrahydroquinoline. When Pd/C and 1,4-cyclohexadiene 39 was used as reducing agent, only reduction of the aliphatic double bond occurred, and after treatment with acid, the desired aldehyde (19b) was obtained. The aldehydes were then reacted under standard conditions with 3′-bromo-5′-chloro-2′-hydroxyacetophenone to yield 20a−b in moderate yields.
The tetrasubstituted chromones 21−25 were synthesized as illustrated in Scheme 8. The monobrominated chroman-4-one 21 was obtained by reaction of 2 with CuBr 2 . Treatment of 21 with NaN 3 in DMSO resulted in the formation of amine 22, 40 which was acetylated with acetyl chloride in pyridine to form 23. A SmI 2 -mediated Reformatsky type reaction using tosyl cyanide as described earlier by Ankner et al. was successfully applied to introduce a nitrile moiety in the 3-position, and subsequent oxidation with DDQ in dioxane yielded 3-cyanochromone 24. 41 Further reduction of the nitrile group by means of DIBAL-H furnished enaminone 22 in 66% yield.
Molecular Modeling. Mode of Action of Sirtuins and Inhibitor Binding. Sirtuins contain a conserved enzymatic core comprising a Rossmann fold domain and a small domain containing a three-β-stranded zinc binding motif. The Rossmann fold contains six parallel β-strands forming a central β-sheet which is sandwiched between α-helices (number dependent on SIRT isoform) on either side of the β-sheet. 42, 43 Between these domains the binding sites of NAD + and the acetylated peptide substrate are located. The NAD + binding site can be formally divided into the subpockets A (adenine binding site), B (ribose binding site), and C (nicotinamide binding site). 42 The binding of the peptide substrate and NAD + is proposed to take place in a sequential manner. 44 Binding of the peptide substrate induces the cleft between the two domains to close, and upon NAD + binding the cofactor binding loop gets ordered. 43, 45 The presence of an acetyl lysine peptide promotes a strained, productive NAD + conformation, which is required for the deacetylation reaction to proceed. This conformation positions the nicotinamide moiety of NAD + in the C-pocket and brings the ribose ring in vicinity of the acetyl group in the peptide substrate. (31), 47 3-arylideneindolin-2-ones (32), 48 salermide (33), 49 cambinol (34), 50 and splitomicin analogues (35) 51 and 36. 52 We therefore wanted to investigate whether this pocket could be a feasible binding site also for our compounds.
Homology Modeling of Human SIRT2. Four crystal structures of SIRT2 are currently available. 53−55 Two of these are apo-structures (PDB codes 1J8F and 3ZGO (3ZGO is a rerefined structure of the human SIRT2 apoenzyme 1J8F)), 53, 54 lacking both peptide substrate and NAD + in their catalytic site. Their structures differ considerably compared to structures where peptide substrate and/or NAD + are bound. Another SIRT2 structure in complex with ADP-ribose (ADPr) was recently solved (3ZGV). 54 ADPr is similar to NAD + in structure; it binds in the NAD + binding cleft and thereby induces the conformational change which closes the active site crevice around ADPr in the Rossmann-fold domain. The fourth structure (4L3O) is a complex of SIRT2 with inhibitor S2iL5, which is a macrocycle binding from the outside into the peptide binding channel. 55 Because the structure with ADPr (3ZGV) lacks a bound inhibitor and includes ADPr instead of NAD + and the macrocycle in the latest solved structure (4L3O) largely differs from the small molecular chroman-4-ones, we decided to construct a homology model of SIRT2 based on a more suitable template.
Recently, crystal structures were published of both SIRT3 and Sir2Tm with (S)-36 (Chart 2) present in the C-pocket. 52 Also SIRT1 binding (S)-37 (Chart 2) has been crystallized. 56 The Sir2Tm structure (PDB code 4BV2) is a complex which includes NAD + , (S)-36, and a peptide substrate, but as it has a rather low resolution (3.3 Å) it was considered not to be the most suitable template for homology modeling. The structures that are solved of SIRT3 with inhibitor (S)-36 (PDB 4BV3) and SIRT1 with (S)-37 (PDB 4I5I) bound in the C-pocket seemed suitable as the size and shape of these compounds are similar to the chroman-4-one-based inhibitors. Of the two structures considered, the SIRT3/NAD + /(S)-36 structure (PDB 4BV3) binds NAD + in a nonproductive mode, with the nicotinamide moiety rotated 180°relative to the C-pocket and instead positioned in the peptide binding channel. Like (S)-36 and (S)-37, the chroman-4-ones do not appear to be peptide substrate competitive inhibitors (data not shown), therefore the SIRT1/NAD + /(S)-37 complex (PDB code 4I5I) was chosen as a template for homology modeling. 56 Models were constructed that included a lysine residue from a Sir2-p53 peptide−NAD + complex (2H4F) 46 57 using the template (SIRT1 human, 4I5I (Q96EB6)), 56 the main target (SIRT2 human, Q8IXJ6), and the human SIRT3 sequence (Q9NTG7). The alignment was fine-tuned to improve the final homology model ( Figure S1 , Supporting Information). A detailed description of the homology modeling procedure is given in the Supporting Information. The force field used in the homology modeling in this study was Amber12:EHF with R-Field solvation, as implemented in the MOE software.
During the construction of the homology model, inhibitor 6f was positioned in the C-pocket close to the location of 37 in the SIRT1 structure in order to achieve more information regarding the inhibitor−enzyme interactions. NAD + was included in the modeling procedure with its geometry kept from the SIRT1 structure, i.e., in its nonproductive mode. The lysine residue from a Sir2-p53 peptide−NAD + complex (2H4F) was included, 46 as were five structural water molecules from the SIRT1 structure (4I5I) positioned within 5 Å from the inhibitor (W2, W5, W17, W74, and W78). The selected inhibitorinduced SIRT2 homology model showed good geometrical properties (see Ramanchandran plots in Figure S2 in the Supporting Information). In the resulting homology model the chroman-4-one scaffold of inhibitor 6f is buried in a hydrophobic and well-defined binding pocket. The carbonyl oxygen of 6f forms a hydrogen bonding interaction with a conserved water molecule W17 (Figure 1) . 52, 54, 58 There is also a halogen bonding interaction from the chloride in the 6-position to the backbone carbonyl of His187 with a distance of 3.7 Å (Cl···O) and an angle of 163.5°(C−Cl···O), which is an acceptable geometry. 59 The bromide in the 8-position is located in a hydrophobic environment surrounded by Leu103, Phe119, Leu138, and Phe190. In addition, Phe96 is favorably positioned for π−π interaction with the halogen substituted aromatic ring of 6f 60 although this interaction is not geometrically optimal as the rings are arranged in a shape which is in between a parallel displacement and a face-to-edge arrangement (r = 5.4 Å, θ = 53.7°, ω = 35.1°, for definition see Figure S3 in Supporting Information). 61 The 2-(pyridin-3-yl)ethyl moiety is positioned in a rather narrow hydrophobic channel (Figure 1 ), which is directed toward the surrounding solution. The pyridine nitrogen of 6f forms a hydrogen bond with Gln142 but could instead easily interact with surrounding water molecules outside the enzyme (Figure 1a,b) .
Evaluation of Inhibitory Activity. The inhibitory effect of the synthesized chroman-4-one/chromones on the activity of SIRT2 was evaluated using a fluorescence-based assay. Table 1 summarizes the results from the SIRT2 inhibition assay of the trisubstituted chroman-4-ones. For potent inhibitors, IC 50 values were determined, and these compounds were also tested against SIRT1 and SIRT3. In general, highly potent inhibitors showed to be selective for the SIRT2 subtype (for SIRT1 and SIRT3 inhibition data, see Table S3 in Supporting Information).
The SIRT2 inhibition data for the tetrasubstituted chromones are summarized in Table 2 . These chromonebased derivatives are moderately potent and selective SIRT2 inhibitors ( Table 2) .
Potent inhibitors were also tested for their inhibitory effect on members of other classes of HDACs. The test confirmed that the compounds exclusively inhibit the class III of lysine deacetylases (HDAC inhibition <10% at 200 μM, data not shown).
Physicochemical properties of this new series of chroman-4-one-/chromone-based inhibitors were calculated (Table S4 , Supporting Information). The results indicate that the structural modifications did lead to less lipophilic compounds with improved physicochemical properties. As illustrated in Table 3 , the potent inhibitors of the new series have similar inhibitory activity as lead compounds 1 and 2, however they exhibit more attractive physicochemical properties such as decreased clogP and clogD-values as well as a larger PSA (Table 3) . Among the synthesized compounds, derivatives 6f and 12a were chosen for evaluation of a potential antiproliferative effect (see below Figure 3 ). Although the methyl ester 9b is the most potent inhibitor and 9a is as active as 12a, the methyl ester group is prone to hydrolysis in the cellbased assay, yielding the biologically inactive carboxylic acids analogues 10a and 10b, therefore 9a and 9b were not further investigated. Structure−Activity Relationships. In this study, we have focused on chroman-4-ones/chromones with increased hydrophilicity. This was achieved by the introduction of aliphatic and aromatic mono/bicyclic moieties with hydrogen-bonding groups in the 2-position of the chroman-4-ones as well as the implementation of hydrogen bonding groups in the 3-position of the chromones. These changes were done to improve the inhibition of SIRT2 but also to obtain information about space limitations caused by the introduction of bulkier groups.
The substituent in the 2-position is crucial for SIRT2 inhibition because 6-bromochroman-4-one lacking a substituent in the 2-position does not show any inhibition (data not shown), while the corresponding analogue 6h, which has a pentyl group in the 2-position, shows an inhibitory activity of 70% (Table 1) . Replacement of the pentyl side chain in lead compound 1 with a more polar ethylene glycol side chain (6d) resulted in a significant decrease in activity (33% inhibition) as did the introduction of a terminal hydroxyl group (6a, 18% inhibition). However, by increasing the length of the linker between the OH-group and the scaffold (6b and 6c), some activity could be retained (Table 1) . Still, 6c (67% inhibition) is less potent then the lead compound ((rac)-1, 88%). This indicates that highly polar side chains (6d) and hydrogen bond donating groups are not favorable with a chain length up to five atoms. This observation can be explained by the homology model, which shows that five out of seven amino acids surrounding this channel are hydrophobic (Ile93, Pro94, Leu103, Leu138, and Phe143, Figure 1a and Figure S1 in the Supporting Information). One of two hydrophilic amino acids (Asp170) is rotated away from the substituent in the 2-position while the other (Gln142) is directed toward the aqueous solution, which might explain the enhanced activity with increasing length of the spacer for alcohols 6a−c. Replacement of the phenyl ring in 2 with a pyridyl moiety (6e−g) resulted in compounds with similar activity and improved solubility. The 3-pyridyl substituted chroman-4-one (6f) was with 86% inhibition most potent compared to the 2-and 4-pyridyl analogues 6e and 6g. Modeling results showed that the pyridyl moiety of 6f has an optimal geometry to form a hydrogen bond with Gln142, which is located at the end of the hydrophobic channel toward the aqueous solution (Figure 1b ). This hydrogen bonding interaction can also be observed for the ester functionality in 9a and 9b, the latter being one of the most potent inhibitors with an IC 50 value of 2.0 μM. As earlier mentioned, esters are prone to hydrolysis under physiological conditions and therefore also the corresponding acids were investigated. However, the carboxylic acids 10a and 10b were completely inactive, which could be attributed to carboxylate formation at physiological pH. Negatively charged groups are unfavorable in the lipophilic and narrow channel accommodating the R 2 -substituent. The replacement of the methyl ester in 9a−b with a methyl amide (11a and 11b) dramatically lowered the activity. Also replacement of the methyl amide with the bulkier iso-propyl (11c) or benzyl amides (11d) gave no increase in inhibitory potency. Only the dimethyl amide 11e was slightly more potent, with 53% inhibition compared to 39% for the monomethyl amide. The secondary amides (11a−d) can act both as hydrogen bond accepting and donating group, and here it seems as the presence of an NH-group decreases the activity. However, all amide analogues are not as active as the methyl esters (9a−b). An explanation for this could be that an NH-group is less favorable in the lipophilic environment than the less hydrophilic single bonded oxygen of the ester. This statement was supported in docking studies 62, 63 of 9b and 11b, where the O-and N-methyl groups are positioned in a small hydrophobic pocket rather than toward the aqueous solution ( Figure 2) . Thereby, the single-bonded oxygen in the ester and the NH-moiety in the amide are oriented toward the hydrophobic site, which makes the more polar amide unfavorable compared to the ester. Compound 11e is still less active than 9b, which could be explained by the steric bulk of the dimethyl amide in the narrow tunnel.
The oxadiazole derivative with an ethylene linker (12a, IC 50 = 12.2 μM) was equipotent to the corresponding methyl ester. Surprisingly, the bioisosteric replacement of the methyl ester moiety of 9b with an oxadiazole group (12b) resulted in lower potency. Docking studies showed that 12a can adopt a similar binding pose as the ester whereas the methyl group of the longer oxadiazole 12b did not fit in the binding channel. The morpholine-and piperidine-substituted analogues 17a and 17b showed 17% and 40% inhibition, respectively. The morpholine and piperidine moieties are rather bulky, and the extended spacer places the groups further away from the scaffold and closer to the narrow part of the channel. Beside this, piperidine and morpholine are charged at pH 7.4, which seems unfavorable in the hydrophobic binding pocket. The chroman-4-one derivatives with the quinolinone and quinoline moieties (20a and b) were moderate inhibitors with 59% and 56% inhibition, respectively. These results are consistent with a previously published indolyl-substituted derivative, 32 which had 53% inhibitory activity. The rather narrow hydrophobic channel accommodating the side chain seems to be large enough to accommodate monocyclic ring systems rather than the large bicyclic moieties. Interestingly, the 6-bromo-8-chloro-chroman-4-one derivative 6i (IC 50 1.8 μM) showed twice the activity of racemic 1 (IC 50 4.3 μM), which strengthens the hypothesis of a halogen bonding interaction between the halide in the 6-position and the backbone carbonyl. A bromide is a better halogen bonding group than chloride, and therefore 6i was supposed to be more active than lead compound 1.
The chromones (Table 2) with an additional substituent in the 3-position showed generally only moderate inhibitory activity (50−81%). The acetamide substituted phenethylchromone 23 was the best inhibitor, with 81% inhibition and an IC 50 value of 29 μM. The introduction of the small Figure 3 . SIRT2 inhibitors reduce A549 (left) and MCF-7 (right) cancer cell proliferation. The cells were treated with 0−100 μM of 6f and 12a. Cell proliferation was determined by a sulforhodamine B assay. The results are shown as mean ± SEM of two to three independent experiments. The asterisks indicate significant differences (* P < 0.05, *** P < 0.001 when compared to controls). heterofunctional side chain on the flat ring system did not result in the desired increase in potency via additional hydrogen bonding interactions.
Evaluation of Antiproliferative Properties. We have previously shown that SIRT1/2/3 pan-inhibitors 64 with a welldocumented mechanism of sirtuin inhibition 45, 65 can cause antiproliferative effects in MCF-7 breast cancer and A549 lung cancer cell lines. Literature reveals that also SIRT2 inhibitors have been shown to have an antiproliferative effect in MCF-7 breast cancer cells 30, 66 and A549 lung cancer cells. 31 We therefore wanted to study whether the novel compounds could achieve similar effects. Two potent inhibitors (6f, 12a) with acceptable physicochemical profiles were chosen for testing in cancer cell proliferation assays. These two human cancer cell lines were exposed to increasing concentrations of 6f and 12a, and the cell proliferation was measured using a sulforhodamine B assay. Both compounds had a strong inhibitory effect on cancer cell growth ( Figure 3) . Compound 6f showed a significant antiproliferative effect already at 10 μM concentration, and under microscopic evaluation there were no living cells visible after 48 h with higher concentrations (≥50 μM) of 6f (data not shown).
SIRT2 is known to deacetylate α-tubulin. 67 To confirm the functionality of 6f and 12a as SIRT2 inhibitors in a cellular environment, MCF-7 cells were treated with these compounds and subjected to Western blot analysis of α-tubulin acetylation levels. After 6 h, treatment with 100 μM 6f had produced a drastic increase in acetylated α-tubulin and lower concentrations of 6f had weaker effects to the same direction ( Figure  4) . After 18 h, all cells treated with 100 μM 6f had died and no sample could be obtained for Western blotting. Nevertheless, 6f gave significant levels of inhibition of α-tubulin deacetylation at lower concentrations at this time point. Treatments with 50 and 100 μM of 12a decreased total α-tubulin after 18 h. When compared to total α-tubulin, there was a clear, albeit nonsignificant trend toward increased α-tubulin acetylation in these samples.
Flow cytometric cell cycle analysis was performed in order to examine the basis for the antiproliferative effects of 6f and 12a. Treatment of MCF-7 or A549 cells for 18 h with 100 μM 12a resulted in cell cycle arrest, as there was a significant increase in the fraction of cells in G 1 /G 0 phase and a significant decrease in the fraction of cells in DNA synthesis phase ( Figure 5) . Furthermore, the fraction of A549 cells in G 2 phase decreased. Treatment with 50 μM 6f also resulted in similar cell cycle arrest in A549 cells (significant) and MCF-7 cells (trend) ( Figure 5 ). No apoptosis was observed in any of the samples (data not shown). The G 1 /G 0 arrest is not necessarily resulting from increased acetylation of α-tubulin but may result from some other SIRT2-mediated event, and similar observations have been found in the literature.
31,68−70
■ CONCLUSION A series of chroman-4-ones carrying heterofunctional groups in the side chain in the 2-position together with four tetrasubstituted chromones were synthesized in good yields using efficient synthetic methods. Compared to the previously published chroman-4-ones, calculations of the physicochemical properties indicate that the new compounds show improved pharmacokinetic properties. Analogues carrying hydrogen bond accepting groups, e.g., pyridyl or ester moieties, were highly potent and selective SIRT2 inhibitors with low micromolar IC 50 values. Two compounds (6f and 12a) were chosen for investigation of their effects on cell proliferation in MCF-7 breast cancer and A549 lung cancer cells. Both compounds showed antiproliferative effects which correlate with their SIRT2 inhibition potency. SIRT2 is likely to be the target in the cancer cell lines, as we could show that the degree of acetylation of α-tubulin increased in a dose-dependent manner. A homology model of SIRT2 based on a SIRT1 crystal structure was built, and docking studies clarified the binding mode of the chroman-4-one-based inhibitors. The proposed binding mode of our compounds was similar to other reported SIRT inhibitors in that they occupy the nicotinamide binding site and prevent NAD + to bind in a catalytically active conformation. The docking studies contributed also to a deeper understanding of the SAR data. However, the reasons behind the isoform selectivity of the chroman-4-ones are still unclear but work is ongoing to get an understanding of the selectivity profile and to verify the binding mode.
■ EXPERIMENTAL SECTION
General. All reactions were carried out using magnetic stirring under ambient atmosphere if not otherwise noted. Room temperature corresponds to a temperature interval from 20 to 21°C. All starting materials and reagents were obtained from commercial producers and were used without prior purification. Solvents were generally used as supplied by the manufacturer. Microwave reactions were carried out using a Biotage Initiator Sixty with fixed hold time modus in 0.5−2, 2− 5 mL, or 10−20 mL capped microwave vials. All reactions were monitored by thin-layer chromatography (TLC) on silica plated aluminum sheets (Silica gel 60 F254, E. Merck). Spots were detected by UV light (254 or 365 nm). Purification by flash column Figure 5 . Effects of SIRT2 inhibitors on A549 (left) and MCF-7 (right) cell cycles. The cells were subjected to control treatment (0.5% DMSO) or treatment with 6f (50 μM) or 12a (100 μM) for 18 h. Flow cytometric analysis of DNA content was done after propidium iodide staining. Percentage of cells in each phase of the cell cycle (G 1 /G 0 , S, and G 2 /M) is indicated. The results are shown as mean ± SEM of two to four independent experiments. The asterisks indicate significant differences (* P < 0.05, ** P < 0.01, *** P < 0.001 when compared to controls). 
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General Procedure for the Swern Oxidation to Obtain Aldehydes 4a−b,d−g. DMSO (3 equiv) was added dropwise to a solution of oxalyl chloride (1.2 equiv) in dry THF (0.1 M) at −78°C under inert atmosphere, and the mixture was stirred for 30 min. The appropriate alcohol (1 equiv) in dry THF (0.5 M) was added dropwise to the reaction mixture, which was stirred for an additional 30 min at −78°C. Et 3 N (5 equiv) was added dropwise, and the mixture was stirred for 15 min before it was allowed to reach room temperature.
Workup Procedure A. Water and EtOAc were added, and the phases were separated. The aqueous phase was extracted with EtOAc, and the combined organic phases were washed with water and brine, dried over MgSO 4 , and filtered, and the solvent was removed under reduced pressure.
Workup Procedure B. The precipitate was filtered off and rinsed thoroughly with EtOAc. The filtrate was concentrated under reduced pressure.
Aldehydes 4a−g were directly used in the next step without further purification and full characterization.
4-(tert-Butyldimethylsilyloxy)butanal (4a). The aldehyde was synthesized according to the general procedure from 4-(tertbutyldimethylsilyl)oxy-1-butanol (1.01 g, 4.93 mmol), DMSO (1.0 mL, 14.1 mmol), oxalyl chloride (0.5 mL, 5.73 mmol), and Et 3 N (3.4 mL, 24.4 mmol). Workup procedure A was used to afford 4a (974 mg). The 1 H NMR spectrum of the crude product was in agreement with data reported in the literature. 71 5-(tert-Butyldimethylsilyloxy)pentanal (4b). The aldehyde was synthesized according to the general procedure from 5-(tertbutyldimethylsilyl)oxy-1-pentanol 3b (2.07 g, 9.48 mmol), DMSO (2.0 mL, 28.4 mmol), oxalyl chloride (1.0 mL, 11.4 mmol), and Et 3 N (6.6 mL, 47.4 mmol). Workup procedure A was used to afford 4b (2.00 g). The 1 H NMR spectrum of the crude product was in agreement with data reported in the literature. 72 6-(tert-Butyldimethylsilyloxy)hexanal (4c). To a suspension of Dess−Martin periodinane (2.06 g, 4.86 mmol) in dry CH 2 Cl 2 (10 mL) at 0°C was dropwise added a solution of 3c (0.75 g, 3.24 mmol) in dry CH 2 Cl 2 (22 mL). The mixture was allowed to reach room temperature and was stirred for 1.5 h. The amount of solvent was reduced to half, the remaining mixture was diluted with Et 2 O, and an aqueous solution of Na 2 S 2 O 3 /NaHCO 3 was added. After 15 min, the phases were separated and the aqueous phase was extracted with EtOAc. The combined organic phases were washed with brine, dried over MgSO 4 , filtered, and concentrated under reduced pressure. The 1 H NMR spectrum of the crude product was in agreement with data reported in the literature. 73 2-(2-Methoxyethoxy)acetaldehyde (4d). The aldehyde was synthesized according to the general procedure from 2-(2-methoxyethoxy)ethanol (1.52 g, 12.6 mmol), DMSO (2.69 mL, 37.9 mmol), oxalyl chloride (1.32 mL, 15.2 mmol), and Et 3 N (8.8 mL, 63.2 mmol). Workup procedure B was used to afford 4d (2.83 mg).
3-(Pyridin-2-yl)propanal (4e). The aldehyde was synthesized according to the general procedure from 3-(pyridine-2-yl)propan-1-ol (71 mg, 0.52 mmol), DMSO (0.11 mL, 1.55 mmol), oxalyl chloride (0.50 mL, 0.62 mmol), and Et 3 N (0.36 mL, 2.59 mmol). Workup procedure A was used to afford 4e (70 mg). The 1 H NMR spectrum of crude product was in agreement with data reported in the literature. 74 3-(Pyridin-3-yl)propanal (4f). The aldehyde was synthesized according to the general procedure from 3-(pyridine-3-yl)propan-1-ol (222 mg, 1.62 mmol), DMSO (0.34 mL, 4.85 mmol), oxalyl chloride (0.17 mL, 1.94 mmol), and Et 3 N (1.13 mL, 8.10 mmol). Workup procedure A was used to afford 4f (420 mg). The 1 H NMR spectrum of the crude product was in agreement with data reported in the literature. 74 3-(Pyridin-4-yl)propanal (4g). The aldehyde was synthesized according to the general procedure from 3-(pyridine-4-yl)propan-1-ol (136 mg, 0.99 mmol), DMSO (0.21 mL, 2.97 mmol), oxalyl chloride (0.10 mL, 1.19 mmol), and Et 3 N (0.69 mL, 4.96 mmol). Workup procedure A was used to afford 4g (263 mg). The 1 H NMR spectrum of the crude product was in agreement with data reported in the literature. 74 General Procedure for Synthesis of Chroman-4-ones 6a−i. The appropriate aldehyde (1.0 equiv) (commercially available or synthesized from the corresponding alcohol as mentioned above) and DIPA (1.1 equiv) were added to a 0.4 M solution of the appropriate 2′-hydroxyacetophenone (1.1 equiv) in EtOH. The mixture was heated by microwave irradiation at 170°C for 1−2 h (fixed hold time, normal absorption), and the solvent was removed in vacuo. The residue was dissolved in EtOAc and washed with 10% NaOH (aq), 1 M HCl (aq), water, and finally with brine. The organic phase was dried over MgSO 4 , filtered, and concentrated under reduced pressure. Purification by flash column chromatography gave chroman-4-ones 6d−i. For the synthesis of 6a−c, the corresponding TBDMS-protected chroman-4-ones 5a−c were dissolved in MeOH (0.1 M), Selectfluor (0.2 equiv) was added, and the mixture was heated by microwave irradiation to 150°C for 30 min. The mixture was concentrated and purified by flash column chromatography to give chroman-4-ones 6a− c.
8-Bromo-6-chloro-2-(3-hydroxypropyl)chroman-4-one (6a). The compound was synthesized according to the general procedure from 4a (crude, 974 mg), 3′-bromo-5′-chloro-2′-hydroxyacetophenone (1.28 g, 5.13 mmol), and DIPA (1 mL, 7.1 mmol) to give 5a (2.00 g). An aliquot (460 mg, 1.06 mmol) was further reacted with Selectfluor (77 mg, 0.22 mmol). Flash column chromatography was performed using EtOAc/heptane (2:8 → 6:4) as eluent to afford 6a (280 mg, 78% over three steps) as a white solid; mp 88−89°C. 8-Bromo-6-chloro-2-(4-hydroxybutyl)chroman-4-one (6b). The compound was synthesized according to the general procedure from 4b (crude, 2.00 g), 3′-bromo-5′-chloro-2′-hydroxy-acetophenone (2.65 g, 10.6 mmol), and DIPA (1.95 mL, 13.8 mmol). The obtained chroman-4-one 5b (3.04 g) was directly reacted with Selectfluor (480 mg, 1.35 mmol). Flash column chromatography was performed using EtOAc/heptane (2:8 → 6:4) as eluent to afford 6b (1. 78 8-Bromo-6-chloro-2-((2-methoxyethoxy)methyl)chroman-4-one (6d). The compound was synthesized according to the general procedure from 4d (crude, 50 mg), 3′-bromo-5′-chloro-2′-hydroxyacetophenone (106 mg, 0.42 mmol), and DIPA (86 μL, 0.85 mmol). Flash column chromatography was performed using EtOAc/heptane (3:7) as eluent to afford 6d (24 mg, 16% over two steps) as an offwhite solid; mp 61 8-Bromo-6-chloro-2-(2-(pyridine-2-yl)ethyl)chroman-4-one (6e). The compound was synthesized according to the general procedure from 4e (crude, 70 mg), 3′-bromo-5′-chloro-2′-hydroxyacetophenone (130 mg, 0.53 mmol), and DIPA (0.1 mL, 0.71 mmol). Flash column chromatography was performed using EtOAc/heptane (2:8 → 55:45) as eluent to afford 6e (102 mg, 54% over two steps) as a gray−black solid; mp 68−70°C. 8-Bromo-6-chloro-2-(2-(pyridin-4-yl)ethyl)chroman-4-one (6g). The compound was synthesized according to the general procedure from an aliquot of 4g (crude, 134 mg), 3′-bromo-5′-chloro-2′-hydroxyacetophenone (247 mg, 0.99 mmol), and DIPA (0.15 mL, 1.06 mmol). Flash column chromatography was performed using EtOAc/heptane (3:7 → 100% EtOAc) as eluent to afford 6g (200 mg, 29% over two steps) as an off-white solid; mp 121−123°C. 6-Bromo-2-pentylchroman-4-one (6h). The compound was synthesized according to the general procedure from 5′-bromo-2′-hydroxyacetophenone (504 mg, 2.34 mmol), hexanal (0.31 mL, 2.58 mmol), and DIPA (0.37 mL, 2.63 mmol). Flash column chromatography was performed using toluene/heptane (1:1) as eluent to afford 6h (433 mg, 62%) as a white solid; mp 42−44°C. 1-(3-Bromo-5-chloro-2-hydroxyphenyl)-2-(tetrahydrofuran-2-yl)ethanone (7a). A solution of TBAF in THF (1 M, 0.18 mL, 0.18 mmol) was added to a stirred solution of 5a (53 mg, 0.12 mmol) in dry THF (11 mL), the reaction mixture was stirred at room temperature overnight. The mixture was concentrated under reduced pressure, and the crude product was purified by flash column chromatography using EtOAc/heptane (1:9) as eluent to afford 7a (30 mg, 76%) as a pale-yellow oil. Methyl 4-Oxobutanoate (8a). Et 3 N (0.24 mL, 1.73 mmol) was added to a solution of γ-butyrolactone (0.40 mL, 5.20 mmol) in MeOH (5 mL). The mixture was stirred overnight at room temperature. Toluene was added, and the solvent was removed under reduced pressure to give the crude methyl 4-hydroxybutanoate as a colorless liquid. DMSO (0.74 mL, 10.4 mmol) was added dropwise to a solution of oxalyl chloride (0.36 mL, 4.16 mmol) in dry THF (21 mL) at −78°C under inert atmosphere, and the mixture stirred for 30 min. Methyl 4-hydroxybutanoate (410 mg, 3.47 mmol) in dry THF (7 mL) was added dropwise to the reaction mixture which was stirred for an additional 30 min at −78°C. Et 3 N (2.42 mL, 17.3 mmol) was added dropwise, and the mixture was stirred for 15 min and was then allowed to reach room temperature. Water and EtOAc were added, and the phases were separated. The aqueous phase was extracted with EtOAc, and the combined organic phases were washed with water and brine, dried over MgSO 4 , and filtered, and the solvent was removed under reduced pressure to give 8a (293 mg, 43% over two steps). The crude product was sufficiently pure to be used in the next step without further purification. The 1 H NMR spectrum of crude product was in agreement with data reported in the literature. 75 Methyl 5-Hydroxypentanoate (8b). Et 3 N (2.0 mL, 14 mmol) was added to a solution of δ-valerolactone (4.2 g, 42 mmol) in MeOH (40 mL). The mixture was stirred for 18 h at room temperature. Toluene was added, and the solvent was removed under reduced pressure. A part of the crude alcohol (2.7 g, 20 mmol) and Et 3 N (8.2 mL, 59 mmol) were dissolved in dry DMSO (40 mL) under inert atmosphere. A solution of SO 3 ·pyridine (9.3 g, 59 mmol) in DMSO (30 mL) was added dropwise, and the mixture was stirred for 14 h at room temperature. The mixture was poured on brine (400 mL) and ice (100 mL), and the product was extracted with CH 2 Cl 2 and EtOAc. The combined organic phases were dried over Na 2 SO 4 , filtered, and concentrated under reduced pressure. Purification by flash chromatog-raphy using EtOAc/hexane (2:8) gave 8b (1.68 g, 63% over two steps). The 1 H NMR spectrum of crude product was in agreement with data reported in the literature. 76 Methyl 3-(8-Bromo-6-chloro-4-oxochroman-2-yl)-propanoate (9a). 3′-Bromo-5′-chloro-2′-hydroxyacetophenone (591 mg, 2.37 mmol) was dissolved in EtOH (10 mL), DIPA (0.36 mL, 2.58 mmol) and 8a (250 mg, 2.15 mmol) were added to a microwave vial, and the mix was heated in the microwave to 170°C for 1 h. The solvent was removed, and the residue was redissolved in EtOAc. The organic phase was washed with 0.1 M HCl (aq), 1% and 10% NaOH (aq), water, and brine. The organic phase was dried over MgSO 4 and filtered, and the solvent was removed under reduced pressure. Purification by flash chromatography using EtOAc:pentane (1:4) gave 9a (300 mg, 40%) as an off-white solid; mp 102−104°C. 1 Methyl 4-(8-Bromo-6-chloro-4-oxochroman-2-yl)butanoate (9b). 3′-Bromo-5′-chloro-2′-hydroxyacetophenone (242 mg, 0.97 mmol), 8b (139 mg, 1.07 mmol), and piperidine (0.01 mL, 0.97 mmol) were added to a microwave vial followed by EtOH (2 mL). 3-(8-Bromo-6-chloro-4-oxo-chroman-2-yl)propanoic acid (10a). To a solution of 6a (378 mg, 1.18 mmol) in dry CH 2 Cl 2 (15 mL) Dess−Martin periodinane (785 mg, 1.80 mmol) was added. The mixture was stirred for 1 h at room temperature. The reaction was quenched by the addition of 10% Na 2 S 2 O 3 /NaHCO 3 (aq). After 5 min, the mix was diluted with CH 2 Cl 2 and H 2 O and the aqueous phase was extracted with CH 2 Cl 2 . The combined organic phases were washed with brine, dried over MgSO 4 , filtered, and concentrated under reduced pressure. The crude aldehyde (387 mg) was dissolved in THF (30 mL) and cooled to 0°C. Amylene (1.25 mL, 11.8 mmol) was added, and NaClO 2 (321 mg, 3.55 mmol) and NaH 2 PO 4 ·2H 2 O (371 mg, 2.37 mmol) dissolved in H 2 O (14 mL) were added dropwise. The ice bath was removed, and the mixture was stirred for 1 h. The reaction was quenched by the addition of a mixture of 1 M HCl and brine (1:1) and EtOAc. After 5 min of stirring, the phases were separated and the aqueous phase was extracted with EtOAc. The combined organic phases were washed with 1 M HCl/brine mix. The organic phase was extracted with 0.1 M NaOH (aq). The basic aqueous phase was acidified with 1 M HCl, and the acidic aqueous phase was extracted with EtOAc. The combined organic phases were finally washed with brine, dried over MgSO 4 , filtered, and concentrated under reduced pressure. Flash column chromatography was performed using EtOAc/heptane (3:7) with 1% AcOH as eluent to afford 10a (290 mg, 73% over two steps) as a white solid; mp 177−179°C. 4-(8-Bromo-6-chloro-4-oxo-chroman-2-yl)butanoic Acid (10b). To a solution of 6b (935 mg, 2.80 mmol) in dry CH 2 Cl 2 (40 mL) Dess−Martin periodinane (1.82 g, 4.16 mmol) was added. The mixture was stirred for 45 min at room temperature. The reaction was quenched by the addition of 10% Na 2 S 2 O 3 /NaHCO 3 (aq). After 5 min, the mix was diluted with CH 2 Cl 2 and H 2 O and the aqueous phase was extracted with CH 2 Cl 2 . The combined organic phases were washed with brine, dried over MgSO 4 , filtered, and concentrated under reduced pressure. The crude aldehyde (1.14 g) was dissolved in THF (70 mL) and cooled to 0°C. Amylene (1.96 g, 28.0 mmol) was added, and NaClO 2 (762 mg, 8.42 mmol) and NaH 2 PO 4 ·2H 2 O (875 mg, 5.61 mmol) dissolved in H 2 O (33 mL) were added dropwise. The ice bath was removed, and the mixture was stirred for 2.5 h. The reaction was quenched by the addition of a mixture of 1 M HCl and brine (1:1) and EtOAc. After 5 min of stirring, the phases were separated and the aqueous phase was extracted with EtOAc. The combined organic phases were washed with brine/1 M HCl mix. The organic phase was extracted with 0.1 M NaOH. The basic aqueous phase was acidified with 1 M HCl (aq), and the acidic aqueous phase was extracted with EtOAc. The combined organic phases were finally washed with brine, dried over MgSO 4 , filtered, and concentrated under reduced pressure. Flash chromatography was performed using EtOAc/heptane (3:7) with 1% AcOH to afford 10b (716 mg, 74% over two steps) as an offwhite solid; mp 123−124°C. General Procedure for the Synthesis of Amides 11a−e. A 0.14 M solution of the appropriate carboxylic acid (1 equiv) in dry CH 2 Cl 2 containing 5−10 vol % DMF was cooled to 0°C under inert atmosphere. N,N′-Carbonyldiimidazole (1.5 equiv) was added, and the mixture was stirred for 30 min. The appropriate amine (3 equiv) was added, and the mixture was stirred at room temperature for 2−14 h. The mixture was diluted with CH 2 Cl 2 and washed with 1 M HCl (aq) and brine, dried over MgSO 4 , filtered, and concentrated under reduced pressure. Purification by flash chromatography gave the amides 11a−e. 8-Bromo-6-chloro-2-(2-(3-methyl-1,2,4-oxadiazol-5-yl)-ethyl)chroman-4-one (12a). To a solution of 10a (100 mg, 0.30 mmol) in MeCN (3 mL) and DMF (0.6 mL) were added N,N′-carbonyldiimidazole (73 mg, 0.45 mmol) and acetamide oxime (34 mg, 0.45 mmol). The mixture was heated to 85°C for 19 h. EtOAc and water were added, and the aqueous phase was extracted with EtOAc. The combined organic phases were washed with 1% NaOH (aq) and brine, dried over MgSO 4 , filtered, and concentrated under reduced pressure. Flash chromatography was performed using MeOH/ CH 2 Cl 2 (2:98) to afford 12a (76 mg, 68%) as a yellow oil. 3-(tert-Butyldimethylsilyloxy)propanal (15) . DMSO (0.60 mL, 8.46 mmol) was added dropwise to a solution of oxalyl chloride (0.37 mL, 4.24 mmol) in dry THF (30 mL) under N 2 atmosphere at −78°C
. The reaction mixture was stirred for 40 min, followed by the dropwise addition of 3-(tert-butyldimethylsilyl)oxy-1-propanol (700 mg, 3.68 mmol) in dry THF (12 mL). The mixture was stirred for additional 45 min at −78°C. Et 3 N (3 mL, 21.52 mmol) was added dropwise, and the mixture was stirred for 15 min at −78°C and was then allowed to warm to room temperature. Water and CH 2 Cl 2 were added, and the phases were separated. The aqueous phase was extracted with CH 2 Cl 2 , and the combined organic phases were washed with water and brine, dried over MgSO 4 , filtered, and concentrated under reduced pressure. 15 (670 mg 97%) was afforded as a colorless oil which was used without further purification.
1 H NMR (CDCl 3 ) δ 3-(8-Bromo-6-chloro-4-oxochroman-2-yl)propyl methanesulfonate (16) . Mesyl chloride (52 μL, 0.67 mmol) was added to a solution of 6a (150 mg, 0.47 mmol) and Et 3 N (0.1 mL, 0.72 mmol) in dry CH 2 Cl 2 (4 mL) at 0°C under inert atmosphere. The mixture was stirred for 2 h and was then washed with water and brine, dried over MgSO 4 , filtered, and concentrated under reduced pressure to afford 16 (180 mg, 96%) as a yellow solid. The product was used in the next step without further purification. 3-(2-Oxo-1,2-dihydroquinolin-6-yl)propanal (19a). 6-Bromoquinolin-2(1H)-one (303.2 mg, 1.35 mmol), Pd(OAc) 2 (31 mg, 0.14 mmol), KCl (102 mg, 1.36 mmol), K 2 CO 3 (282 mg, 2.04 mmol), and TBAA (820 mg, 2.71 mmol) were dissolved in dry DMF (6 mL) under inert atmosphere. Acrolein diethyl acetal (0.62 mL, 4.06 mmol) was added, and the mixture was heated at 90°C overnight. The reaction was divided in three runs. The mixtures were diluted with EtOAc, filtered through Celite, rinsed with EtOAc, and concentrated under reduced pressure and coevaporated with toluene to afford 18a as brown oil (1157 mg), which was used in the next step without further purification. 18a was dissolved in MeOH (14 mL), and 10% Pd/C (10 wt %, 111 mg) was added. The mixture was stirred under H 2 atmosphere (balloon) for 3 h at room temperature, filtered through Celite, and the filtrate was concentrated under reduced pressure, resulting in a brown oil (960 mg). The crude oil was dissolved acetone (13 mL), whereafter water (0.6 mL) and HCl (0.5 mL, conc) were added. The mixture was heated to reflux for 4 h. The solvent was removed, and EtOAc and water were added to the residue. The phases were separated, and the aqueous phase was extracted with EtOAc. The combined organic phases were washed with saturated NaHCO 3 (aq), water and brine, dried over Na 2 SO 4 , filtered, and concentrated under reduced pressure. The crude product was purified by flash column chromatography using MeOH/EtOAc (3:97) as eluent, affording the 19a as a pale-yellow solid (97 mg, 34% over three steps); mp 139−141°C 3-(Quinolin-6-yl)propanal (19b). 6-Bromoquinoline (106 mg, 0.51 mmol) was dissolved in dry DMF (2 mL) under inert atmosphere, and Pd(OAc) 2 (12 mg, 0.054 mmol), KCl (38 mg, 0.51 mmol), K 2 CO 3 (108 mg, 0.78 mmol), and TBAA (311 mg, 1.02 mmol) were added. Acrolein diethyl acetal (0.23 mL, 1.53 mmol) was added, and the mixture was heated at 90°C for 24 h. The reaction was divided in three runs in the microwave. The mixtures were diluted with EtOAc, filtered through Celite, rinsed with EtOAc, and concentrated under reduced pressure and coevaporated with toluene to afford 18b as brown oil (471 mg), which was used in the next step without further purification. 18b was dissolved EtOH (10 mL), and 1,4-cyclohexadiene (0.48 mL, 10 mmol) and 10% Pd/C (11 mg, 0.01 mmol) were added. The mixture was heated to reflux for 1.5 h. Two subsequent additions of 1,4-cyclohexadiene (0.23 mL, 2.5 mmol; 0.48 mL, 5.1 mmol) and 10% Pd/C (11 mg, 0.01 mmol and 8 mg, 0.007 mmol) were made after 1.5 and 3 h of heating. The mixture was heated to reflux for 4.5 h in total. The mixture was diluted with EtOAc, filtered through Celite, rinsed with EtOAc, and concentrated under reduced pressure, affording the crude product as a yellow oil (374 mg). The crude oil was dissolved acetone (13 mL), whereafter water (2 mL) and HCl (1 mL, conc) were added. The mixture was heated to reflux for 2 h. The solvent was removed, and EtOAc and saturated Na 2 CO 3 (aq) were added to the residue. The phases were separated, and the aqueous phase was extracted with EtOAc. The combined organic phases were washed with saturated NaHCO 3 (aq), water, and brine, dried over MgSO 4 , filtered, and concentrated under reduced pressure. The crude product was purified by flash column chromatography using EtOAc as eluent to afford 19b as a transparent oil (53 mg, 56% over three steps). 8-Bromo-6-chloro-2-(2-(quinolin-6-yl)ethyl)chroman-4-one (20b). 3′-Bromo-5′-chloro-2′-hydroxyacetophenone (77.1 mg, 0.31 mmol) was dissolved in EtOH (1 mL), DIPA (44 μL, 0.31 mmol) and 19b (52 mg, 0.28 mmol) were added to a microwave vial, and the mixture was heated in the microwave reactor to 170°C for 2 h. The solvent was removed, and the residue was redissolved in EtOAc. The organic phase was washed with 10% NaOH (aq), water, and brine, dried over MgSO 4 , filtered, and concentrated under reduced pressure. The crude product was purified by flash column chromatography using EtOAc/pentane (1:1) as eluent, affording 20b as a pale-yellow solid (18 mg, 15%); mp 187−190°C. (Z)-3-(Aminomethylene)-8-bromo-6-chloro-2-phenethylchoman-4-one (25) . A solution of 24 (0.025 g, 0.06 mmol) in anhydrous THF (2 mL) was cooled to −78°C, and DIBAL-H (0.06 mL, 0.06 mmol, 1 M in CH 2 Cl 2 ) was added dropwise to the mixture. After 1 h at −78°C, a further portion of DIBAL-H (0.06 mL, 0.06 mmol, 1 M in CH 2 Cl 2 ) was added. After 2 h, the reaction was quenched with saturated NH 4 Cl (aq), followed by the addition of EtOAc. The aqueous phase was extracted three times with EtOAc, and the combined organic phases were washed with H 2 O and brine. The organic phase was dried over MgSO 4 In Vitro Fluor de Lys Assay for SIRT1−3 Activities. The Fluor de Lys fluorescence assays were based on the method described in the BioMol product sheet (Enzo Life Sciences) using the BioMol KI177 substrate for SIRT1 and the KI179 substrate for SIRT2 and SIRT3. The determined K m value of SIRT1 for KI177 was 58 μM, and the K m of SIRT2 for KI179 was 198 μM. 77 The K m of SIRT3 for KI179 was reported by BioMol to be 32 μM. The K m values of SIRT1, SIRT2, and SIRT3 for NAD + were reported by BioMol to be 558 μM, 547 μM, and 2 mM, respectively.
Briefly, assays were carried out using the Fluor de Lys acetylated peptide substrate at a concentration corresponding to 0.7 K m and NAD + (N6522, Sigma) at a concentration corresponding to 0.9 K m , recombinant GST-SIRT1/2-enzyme or recombinant His-SIRT3 and SIRT assay buffer (HDAC assay buffer, KI143, supplemented with 1 mg/mL BSA, A3803, Sigma). GST-SIRT1 and GST-SIRT2 were produced as described previously. 78, 79 His-SIRT3 (BML-SE270) was purchased from Enzo Life Sciences. The buffer, Fluor de Lys acetylated peptide substrate, NAD + , and DMSO/compounds in DMSO (2.5 μL in 50 μL total reaction volume; DMSO from Sigma, D2650) were preincubated for 5 min at room temperature. The reaction was started by adding the enzyme. The reaction mixture was incubated for 1 h at 37°C. After that, Fluor de Lys developer (KI176) and nicotinamide (2 mM in HDAC assay buffer giving total volume of 50 μL) were added, and the incubation was continued for 45 min at 37°C
. Fluorescence readings were obtained using EnVision 2104 multilabel reader (PerkinElmer) with excitation wavelength 370 nm and emission 460 nm.
The IC 50 values were determined as three independent determinations with 8−10 different inhibitor concentrations in each determination. This gave altogether 27 data points that were included in the calculation of the best-fit value for nonlinear curve fitting with GraphPad Prism5 (GraphPad Software, Inc.).
Histone Deacetylase (HDAC) Activity Assay. The assay was done according to the instructions of the HDAC fluorimetric assay/ drug discovery kit (AK500, Enzo). Briefly, the assay was carried out using 50 μM Fluor de Lys HDAC substrate (KI104, Enzo) and 200 μM test compounds with HeLa cell nuclear extract (KI410, Enzo) as a source of HDAC enzymatic activity. The reaction mixture was incubated for 1 h at 37°C. After that, Fluor de Lys developer plus 1 μM Trichostatin A was added and incubation was continued for 15 min at 25°C. Fluorescence readings were obtained with EnVision 2104 multilabel reader (PerkinElmer) with excitation wavelength 370 nm and emission 460 nm.
SIRTainty Sirtuin Activity Assay. The fluorometric SIRTainty class III HDAC assay (Millipore) employs nicotinamidase to measure nicotinamide generated upon the cleavage of NAD + during sirtuin mediated deacetylation of a substrate. 80 The SIRT2 activity testing was performed according to the assay instructions in the presence and absence of NAD + . The results were read using Victor 1420 multilabel counter (Wallac) with excitation wavelength 405 nm and emission 460 nm and were reported as % of inhibition of the NAD + -dependent signal.
Cell Culture. Human A549 lung carcinoma cells and MCF-7 breast carcinoma cells (both from ATCC) were maintained in Dulbecco's Modified Eagle Medium (DMEM) containing 10% fetal calf serum, 100 U/mL penicillin, and 100 μg/mL streptomycin (all from Gibco) at +37°C in a humidified atmosphere of 5% CO 2 /95% air.
Cell Proliferation and Cell Cycle Analysis. For cell proliferation assays with sulforhodamine B, the cells were plated to 96-well plates (Nunc) 24 h before the start of the treatments (3000 cells/well). The cells were treated with vehicle (0.5% DMSO) or test compounds for 48 h (A549 cells) or 72 h (MCF-7 cells). Sulforhodamine B staining was performed as previously described. 64 For cell cycle analysis with propidium iodide staining, the cells were plated to 6-well plates (Nunc) 6 h before the start of the treatments (0.6 × 10 6 cells/well). The cells were treated with vehicle (0.5% DMSO) or test compounds for 18 h. Propidium iodide staining was performed as previously described. 64 FACScanto II flow cytometer with FACSDiva software (Becton Dickinson) was used to analyze cellular DNA content and cell cycle.
Western Blotting. The MCF-7 cells were plated to 12-well plates (Nunc) at a density of 10 5 cells/well, and the experiments were initiated after 24 h. The cells were treated with vehicle (0.5% DMSO) or test compounds as previously described. 81 For the analysis of α-tubulin acetylation levels, the cells were lysed into M-PER mammalian protein extraction reagent (Thermo Fisher Scientific) followed by centrifugation (20 min, 16000g, +4°C). After electrophoretic separation in SDS-PAGE gel, the proteins were transferred onto Hybond-ECL nitrocellulose transfer membrane (GE Healthcare) and were detected with mouse monoclonal acetylated α-tubulin antibody (T6793, Sigma) and total α-tubulin antibody (T5168, Sigma). The protein signals were visualized with peroxidase-conjugated sheep antimouse secondary antibody (ab97046, Abcam) and ECL Plus chemiluminescent substrate (GE Healthcare). The images were obtained by the use of digital imaging (ImageQuant, GE Healthcare).
Statistical Analyses. Statistical differences between groups were tested using one-way analysis of variance (ANOVA), followed by Tukey′s Multiple Comparison Test, with p < 0.05 considered as statistically significant. Data analysis was performed using GraphPad Prism version 5.03 for Windows (GraphPad Software).
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